Pain After Tumescent Mastectomy or Standard Mastectomy in Women With Stage I, Stage II, or Stage III Breast Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00859157 |
|
Recruitment Status :
Completed
First Posted : March 10, 2009
Last Update Posted : June 21, 2017
|
Sponsor:
University of California, Davis
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of California, Davis
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
RATIONALE: New surgery techniques may lessen pain after breast surgery. It is not yet known whether tumescent mastectomy or standard mastectomy results in less pain in women with breast cancer.
PURPOSE: This clinical trial is studying pain after tumescent mastectomy compared with pain after standard mastectomy in women with stage I, stage II, or stage III breast cancer.
| Condition or disease | Intervention/treatment |
|---|---|
| Breast Cancer Pain Perioperative/Postoperative Complications | Procedure: therapeutic conventional surgery |
OBJECTIVES:
Primary
- To compare post-operative pain after tumescent vs standard mastectomy in women with stage I-III breast cancer.
Secondary
- To compare the total time of operation from incision to completion of wound closure.
- To compare the time of operation from first incision to completion of skin flaps.
- To compare the total estimated blood loss.
- To compare the number of days the Jackson-Pratt drain is left in place under skin flaps with wound drainage > 30 mL/24 hours.
- To compare the incidence of wound complications such as skin necrosis, hematoma, cellulitis, abscess, and seroma between groups.
OUTLINE: Patients are grouped according to which surgeon provided their evaluation and treatment recommendations.
- Group 1: Patients undergo standard mastectomy.
- Group 2: Patients undergo tumescent mastectomy. All patients receive standardized post-operative pain management comprising morphine sulfate for analgesia or an equivalent dose of hydromorphone hydrochloride for 24 hours following surgery. Patients then receive 1-2 oral acetaminophen/oxycodone hydrochloride combination tablets (or a comparable amount of another narcotic/acetaminophen combination) every 6 hours as needed. Pain is assessed using the Short-form McGill Pain Questionnaire (SF-MPQ).
| Study Type : | Observational |
| Actual Enrollment : | 74 participants |
| Observational Model: | Case-Control |
| Time Perspective: | Prospective |
| Official Title: | Tumescent Mastectomy: A Prospective Comparison to Standard Mastectomy Technique |
| Study Start Date : | October 2008 |
| Actual Primary Completion Date : | January 2014 |
| Actual Study Completion Date : | January 2014 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Breast cancer
| Group/Cohort | Intervention/treatment |
|---|---|
|
Group 1
Patients undergo standard mastectomy.
|
Procedure: therapeutic conventional surgery
Patients undergo tumescent or standard mastectomy |
|
Group 2
Patients undergo tumescent mastectomy.
|
Procedure: therapeutic conventional surgery
Patients undergo tumescent or standard mastectomy |
Primary Outcome Measures :
- Post-operative pain at 1 and at 7-10 days after mastectomy [ Time Frame: 7-10 days ]
Secondary Outcome Measures :
- Number of acetaminophen/oxycodone tablets taken [ Time Frame: 7-10 days after surgery ]
- Total time of operation from breast incision to completion of wound closure [ Time Frame: Day of surgery ]
- Time of operation from first incision to completion of both superior and inferior skin flaps [ Time Frame: Day of surgery ]
- Estimated blood loss [ Time Frame: Day of surgery ]
- Number of days the Jackson-Pratt drain is left in place with wound drainage > 30 mL/24 hours [ Time Frame: 7-10 days after surgery ]
- Wound complications (skin necrosis, hematoma, cellulitis, abscess, and seroma) occurring up to and 10 days post-operatively [ Time Frame: Up to 10 days after surgery ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 120 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Adult (age 18 or more) women with histologic diagnosis of stage 0, I, II, III breast cancer undergoing mastectomy.
Criteria
DISEASE CHARACTERISTICS:
-
Histologically confirmed diagnosis of 1 of the following:
- Invasive (ductal or lobular) breast cancer
- In situ (ductal) breast cancer
- Stage 0-III disease
- Localized disease
- Candidate for curative mastectomy and selected mastectomy or modified radical mastectomy for surgical option of treatment at the University of California Davis Medical Center
- Hormone receptor status not specified
PATIENT CHARACTERISTICS:
- Menopausal status not specified
- WBC ≥ 1,500/mm^3
- Platelet count ≥ 90,000/mm^3
- PT/PTT ≤ upper limit of normal (ULN)
- Creatinine ≤ 1.5 times ULN
- Not pregnant or nursing
- Negative pregnancy test
- No NYHA cardiac disease class III-IV
- Cancer survivors must have undergone potentially curative therapy for all prior malignancies with no evidence of prior malignancy within the last 5 years, except for effectively treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix treated by surgery alone, or lobular carcinoma in situ of the breast treated by surgery alone
- Body Mass Index ≤ 40
PRIOR CONCURRENT THERAPY:
- No prior major breast surgery, including breast augmentation or reduction surgery
- No preoperative chemotherapy or radiotherapy
- No concurrent immediate breast reconstruction
- No concurrent bilateral mastectomy
- No concurrent narcotic pain medication
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00859157
Locations
| United States, California | |
| University of California Davis Cancer Center | |
| Sacramento, California, United States, 95817 | |
Sponsors and Collaborators
University of California, Davis
National Cancer Institute (NCI)
Investigators
| Principal Investigator: | Steve R. Martinez, MD | University of California, Davis |
| Responsible Party: | University of California, Davis |
| ClinicalTrials.gov Identifier: | NCT00859157 History of Changes |
| Other Study ID Numbers: |
246600 UCD-CCSO001 200816282 CDR0000633754 ( Other Identifier: UC Davis ) |
| First Posted: | March 10, 2009 Key Record Dates |
| Last Update Posted: | June 21, 2017 |
| Last Verified: | June 2017 |
Keywords provided by University of California, Davis:
|
perioperative/postoperative complications pain ductal breast carcinoma in situ invasive ductal breast carcinoma invasive lobular breast carcinoma |
stage IA breast cancer stage IB breast cancer stage II breast cancer stage IIIA breast cancer stage IIIB breast cancer |
Additional relevant MeSH terms:
|
Breast Neoplasms Postoperative Complications Neoplasms by Site Neoplasms |
Breast Diseases Skin Diseases Pathologic Processes |